Ductal Adenocarcinoma of the Prostate Gland: Understanding Your Pathology Report

Section Editor: Trevor Flood MD FRCPC
October 25, 2026

Ductal adenocarcinoma of the prostate gland is an uncommon type of prostate cancer. It starts from the glandular cells that line the larger ducts of the prostate, rather than the small glands where most prostate cancers begin. Ductal adenocarcinoma is usually found mixed with the much more common type of prostate cancer, acinar adenocarcinoma. It tends to grow and spread faster than most acinar adenocarcinomas, so it is treated as a high-grade cancer.

This article explains how ductal adenocarcinoma of the prostate is diagnosed and what the findings in your pathology report mean. These findings include the Gleason score and Grade Group, the amount of ductal adenocarcinoma, extraprostatic extension, margins, lymph nodes, stage, and genetic testing.

Who gets ductal adenocarcinoma of the prostate?

Ductal adenocarcinoma of the prostate affects the same group of men as other prostate cancers, usually men over 60. A tumor made only of ductal adenocarcinoma is rare. Ductal adenocarcinoma is found more often as one part of a tumor that also contains acinar adenocarcinoma. Men with inherited changes in certain DNA repair genes, such as BRCA2, are more likely to have ductal or intraductal features in their prostate cancer.

What causes ductal adenocarcinoma of the prostate?

The cause of ductal adenocarcinoma of the prostate is not fully understood. Like other prostate cancers, it develops when glandular cells acquire genetic changes that allow them to grow out of control. Ductal adenocarcinoma more often carries changes in genes that repair damaged DNA, including BRCA2, ATM, and the mismatch repair genes. Some of these changes are inherited and can affect other family members, which is why genetic testing is often discussed.

What are the symptoms of ductal adenocarcinoma of the prostate?

Ductal adenocarcinoma of the prostate can start in the ducts close to the urethra, the tube that carries urine out of the body. Because of this location, it is more likely than acinar adenocarcinoma to cause urinary symptoms. These can include blood in the urine, a weak urine stream, or needing to urinate often. Some men have no symptoms, and the cancer is found because of an abnormal rectal examination or a raised prostate-specific antigen (PSA) blood test. Ductal adenocarcinoma does not always raise the PSA level as much as acinar adenocarcinoma does.

How is the diagnosis made?

The diagnosis of ductal adenocarcinoma of the prostate is usually made on a needle biopsy of the prostate, in which several thin cores of tissue are removed. Tumors that start close to the urethra are sometimes found in tissue removed by a transurethral resection of the prostate (TURP), an operation done to relieve blocked urine flow. A pathologist then examines the tissue under the microscope.

Ductal adenocarcinoma is made up of large glands lined by tall, column-shaped tumor cells. The tumor cells may form finger-like papillary structures, sieve-like cribriform glands, or solid sheets. Some tumors contain areas of dead tumor cells in the center of the glands, called comedonecrosis. Stains such as NKX3.1 and PSA may be used to confirm that the tumor started in the prostate. If the diagnosis is made on a biopsy, imaging such as MRI, CT, a bone scan, or a PSMA PET scan may be used to check for spread.

Mixed ductal and acinar adenocarcinoma

Most ductal adenocarcinomas of the prostate are found together with acinar adenocarcinoma in the same tumor. When both are present, your report may describe the tumor as mixed ductal and acinar adenocarcinoma. Some reports give the approximate percentage of the tumor made up of ductal adenocarcinoma.

The presence of ductal adenocarcinoma matters even when it is only a small part of the tumor. Because ductal adenocarcinoma is graded as Gleason pattern 4, it raises the Gleason score and Grade Group. A small ductal component can also be the first sign that the tumor may behave more like a high-grade cancer.

Gleason score and Grade Group

The Gleason score and Grade Group describe how abnormal the prostate cancer looks under the microscope and help predict how it will behave. The pathologist assigns a Gleason pattern from 3 to 5 to the different areas of the tumor. The two most common patterns are added together to give the Gleason score, which is then converted to a Grade Group from 1 to 5.

Ductal adenocarcinoma of the prostate is graded as follows:

Gleason pattern 4. Most ductal adenocarcinoma is assigned Gleason pattern 4. A tumor made only of this type of ductal adenocarcinoma is usually Gleason score 4+4=8, which is Grade Group 4.
Gleason pattern 5. Ductal adenocarcinoma with comedonecrosis is assigned Gleason pattern 5, the highest pattern.
Mixed tumors. When ductal and acinar adenocarcinoma are mixed, the ductal areas are graded as pattern 4 or 5 and combined with the pattern of the acinar areas. For example, a tumor that is mostly acinar pattern 3 with some ductal adenocarcinoma would be Gleason score 3+4=7, Grade Group 2.

Some prostate cancers have glands that look like high-grade prostatic intraepithelial neoplasia, a precancerous change, but lack the normal outer layer of basal cells. This is called PIN-like carcinoma. The World Health Organization (WHO) classification, 5th edition (2022), considers it a form of acinar adenocarcinoma, not ductal adenocarcinoma. It is graded as Gleason pattern 3 and usually behaves like a low-grade cancer.

Intraductal carcinoma

Intraductal carcinoma differs from ductal adenocarcinoma, although the names are similar. In intraductal carcinoma, cancer cells grow inside existing prostate ducts and glands, which still have their outer layer of basal cells. Intraductal carcinoma is often found together with high-grade acinar or ductal adenocarcinoma. It is linked with a less favorable outlook and with inherited changes in DNA repair genes. Your report will say whether intraductal carcinoma is present.

Tumor quantification

Tumor quantification describes how much of the prostate is involved by cancer. On a biopsy, the report gives the number of cores that contain cancer and the length or percentage of each core involved. After the prostate is removed, the report gives the percentage of the prostate involved by cancer, the size of the largest tumor nodule, or both. Larger amounts of cancer are linked with a higher chance of the cancer coming back.

Extraprostatic extension

Extraprostatic extension means the ductal adenocarcinoma has grown through the edge of the prostate into the surrounding fat or connective tissue. It is only assessed after the whole prostate has been removed in an operation called a radical prostatectomy. Your report may describe extraprostatic extension in one of these ways:

Not identified. The cancer is confined to the prostate.
Focal. Only a few cancer glands are seen outside the prostate.
Nonfocal or established. A larger amount of cancer is seen outside the prostate.

Extraprostatic extension raises the tumor stage to pT3a. Nonfocal extraprostatic extension is linked to a higher chance of cancer recurrence than focal extension. In one study, about 73 in 100 men with focal extension had no progression of cancer five years after surgery. This fell to about 42 in 100 with nonfocal extension.

Seminal vesicle invasion

The seminal vesicles are two small glands behind the prostate that make up part of the fluid in semen. Seminal vesicle invasion means cancer has grown into the muscular wall of a seminal vesicle. Ductal adenocarcinoma is more likely than acinar adenocarcinoma to invade the seminal vesicles. Seminal vesicle invasion raises the tumor stage to pT3b and is linked with a higher chance of the cancer spreading.

Bladder neck invasion

The bladder neck is the lower part of the bladder where it joins the prostate. Bladder neck invasion means cancer cells are seen in the thick muscle of the bladder neck in the removed tissue. When it is seen only under the microscope, bladder neck invasion raises the tumor stage to pT3a, the same stage as extraprostatic extension.

Lymphovascular invasion

Lymphovascular invasion means cancer cells were seen inside a blood vessel or lymphatic channel. These vessels carry blood and fluid away from the prostate, so tumor cells inside them have a route to spread. Your report will describe lymphovascular invasion as present, not identified, or cannot be determined. In prostate cancer, lymphovascular invasion is linked with a higher chance of the PSA rising again after surgery.

Perineural invasion

Perineural invasion means cancer cells were seen along or around a nerve. It is common in prostate cancer, including ductal adenocarcinoma. In prostate cancer, perineural invasion on its own is not a strong predictor of outcome, and some reports do not include it.

Surgical margins

A margin is the cut edge of tissue removed during surgery. After a radical prostatectomy for ductal adenocarcinoma, the pathologist paints the outside of the prostate with ink and checks whether cancer cells touch the ink. Your report will describe the margins in one of these ways:

Negative margin. No cancer cells touch the inked surface, which means the cancer was completely removed. Cancer close to the ink but not touching it is still a negative margin.
Positive margin. Cancer cells touch the inked surface, which means some cancer may remain in the body. The report usually gives the location of the positive margin, its length in millimeters, and the Gleason pattern at the margin.

A positive margin longer than 3 mm, or with a higher Gleason pattern, is linked with a higher chance of the PSA rising again. Your care team will use these details to decide whether you need further treatment, such as radiation.

Lymph nodes

Lymph nodes are small immune organs found throughout the body. Prostate cancer usually spreads first to the lymph nodes in the pelvis. These lymph nodes may be removed during a radical prostatectomy. The pathologist reports how many lymph nodes were examined and how many contained cancer. The report may also give the size of the largest cancer deposit and whether the cancer has broken through the outer capsule of a lymph node, called extranodal extension. Cancer in any pelvic lymph node changes the nodal stage to pN1.

Biomarker and molecular testing

Biomarker testing in ductal adenocarcinoma of the prostate looks for changes in genes that repair damaged DNA. These changes are more common in ductal adenocarcinoma than in acinar adenocarcinoma. The results can identify men who may benefit from specific drugs and families who may have an inherited cancer risk.

BRCA2, BRCA1, ATM, and other DNA repair genes

BRCA2, BRCA1, ATM, and similar genes belong to a group called homologous recombination repair (HRR) genes. They normally help cells repair DNA breaks. These genes can be tested in two ways. Germline testing uses a blood or saliva sample and looks for inherited changes. Tumor testing uses the cancer tissue and looks for changes in the tumor, using next-generation sequencing (NGS).

No pathogenic variant detected. No harmful change was found in the genes tested. This is the most common result.
Pathogenic or likely pathogenic variant detected. A harmful change was found. In men with metastatic castration-resistant prostate cancer, this can make them eligible for a type of drug called a PARP inhibitor. For example, olaparib was approved by the US Food and Drug Administration (FDA) in 2020 for this group after earlier hormone treatment. If the change is inherited, relatives may also be at risk, and genetic counseling is usually recommended.
Variant of uncertain significance. A change was found, but it is not known whether it is harmful. This result is not considered positive.

Our article on BRCA1 and BRCA2 in prostate cancer explains these tests and treatments in more detail.

Mismatch repair (MMR) and microsatellite instability (MSI)

Mismatch repair proteins fix small copying errors in DNA. They can be tested with immunohistochemistry, or the tumor can be tested for microsatellite instability. An MMR-proficient or MSI-stable result is normal and the most common. An MMR-deficient or MSI-high result means the tumor has lost this repair system. This can make a man eligible for immunotherapy and may point to an inherited condition called Lynch syndrome. Our article on mismatch repair and microsatellite instability in prostate cancer explains this testing in more detail.

Not every man with ductal adenocarcinoma will have all of these tests. Our Biomarkers and Genetic Testing section explains these tests in more detail.

Pathologic stage (pTNM)

The pathologic stage of ductal adenocarcinoma of the prostate is based on the removed prostate (pT) and any lymph nodes examined (pN). It uses the TNM staging system in the 8th edition of the AJCC Cancer Staging Manual. The pathologic stage is only given after a radical prostatectomy, not after a biopsy. The pathologist usually determines distant spread (M) by imaging, not by pathology.

Tumor stage (pT)

pT2. The cancer is confined to the prostate, no matter how much of the prostate is involved.
pT3a. The cancer has grown outside the prostate (extraprostatic extension) or into the bladder neck, as seen under the microscope.
pT3b. The cancer has grown into one or both seminal vesicles.
pT4. The cancer has grown into nearby structures other than the seminal vesicles, such as the rectum, the bladder, or the wall of the pelvis.

Nodal stage (pN)

pN0. No cancer is found in any of the lymph nodes examined.
pN1. Cancer is found in one or more pelvic lymph nodes.
pNX. Lymph nodes were not sent for examination.

What is the prognosis?

The prognosis for ductal adenocarcinoma of the prostate is less favorable than for most acinar adenocarcinomas, and closer to that of high-grade acinar cancer (Gleason score 8 to 10). Ductal adenocarcinoma is more often found at a higher stage, with growth outside the prostate or into the seminal vesicles.

In one large study, about 88 in 100 men with ductal adenocarcinoma were alive five years after radical prostatectomy, compared with about 97 in 100 men with acinar adenocarcinoma. About 75 in 100 men with ductal adenocarcinoma had no distant spread at five years, compared with about 95 in 100 with acinar adenocarcinoma. Pathologic features linked with a less favorable outlook include:

Higher Grade Group. Gleason pattern 5, including comedonecrosis, is linked with a higher chance of spread.
A large amount of ductal adenocarcinoma. Tumors made mostly or only of ductal adenocarcinoma behave less favorably than tumors with a small ductal component.
Intraductal carcinoma. Its presence is linked with a less favorable outlook.
Extraprostatic extension or seminal vesicle invasion. Growth outside the prostate raises the stage.
Positive margin. Cancer at the inked surface means some cancer may remain.
Lymph node involvement. Cancer in the pelvic lymph nodes raises the chance of spread to distant organs.

What happens after the diagnosis?

After ductal adenocarcinoma of the prostate is diagnosed, the next steps depend on the Grade Group, the stage, the PSA level, and the results of imaging. Because ductal adenocarcinoma is treated as a high-grade cancer, active surveillance is not usually recommended. A team that includes a urologist, a radiation oncologist, and a medical oncologist usually plans care.

For cancer limited to the prostate or nearby tissue, the options your team may discuss include radical prostatectomy or radiation therapy combined with hormone therapy. Hormone therapy, also called androgen deprivation therapy, lowers testosterone, which prostate cancer cells use to grow. After surgery, findings such as a positive margin, seminal vesicle invasion, or lymph node involvement may lead the team to consider radiation or hormone therapy.

For cancer that has spread, treatment usually includes hormone therapy combined with other drugs. Genetic testing results can open further options, such as a PARP inhibitor for a harmful BRCA2 change or immunotherapy for mismatch repair deficiency. Because ductal adenocarcinoma does not always raise the PSA level, follow-up may include imaging as well as PSA tests. Your oncologist can tell you whether you qualify for any open clinical trials.

Questions to ask your doctor

Is my cancer pure ductal adenocarcinoma, or mixed with acinar adenocarcinoma?
What percentage of my cancer is ductal adenocarcinoma?
What is my Gleason score and Grade Group?
Was comedonecrosis or intraductal carcinoma found?
Did the cancer grow outside the prostate, and was the extension focal or nonfocal?
Did the cancer invade the seminal vesicles or bladder neck?
Were the margins negative, and if not, how long was the positive margin?
Were lymph nodes removed, and did any contain cancer?
What is my pathologic stage?
Should I have germline genetic testing, tumor testing, or both?
If a gene change is found, should my family members be tested?
Will my follow-up include imaging and PSA tests?